Physician profile
Amy E Adams
NPI 1679643928
$880.04
in general payments reported to CMS, 2019-2025
13 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2021: $16.74 · 2023: $148 · 2024: $77.93 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.14 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $148.05 | 2023 | |
| Arcutis Biotherapeutics, INC. | $129.13 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $119.41 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.54 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Almirall LLC | $73.85 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $68.50 | 2025 | |
| Leo Pharma INC. | $68.12 | 2025 | Adbry |
| Celgene Corporation | $65.10 | 2019 | |
| Amgen INC. | $30.50 | 2024 | Otezla |
| Dermavant Sciences, INC. | $26.51 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $17.33 | 2025 | Dupixent |
| Organon LLC | $15.57 | 2025 | Nexplanon |
| Strata Skin Sciences, INC. | $5.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.